From: Cost-effectiveness analysis of guidelines for antihypertensive care in Finland
Initial drug | 1st additional drug | 2nd additional drug |
---|---|---|
thiazide diuretic | ACE inhibitor (or angiotensin II subtype 1 receptor antagonist) | calcium channel blocker or beta blocker |
thiazide diuretic | beta blocker | ACE inhibitor (or angiotensin II subtype 1 receptor antagonist) or calcium channel blocker |
calcium channel blocker (dihydropyridine derivatives) | ACE inhibitor (or angiotensin II subtype 1 receptor antagonist) | thiazide diuretic or beta blocker |
calcium channel blocker | beta blocker | ACE inhibitor (or angiotensin II subtype 1 receptor antagonist) or thiazide diuretic |
ACE inhibitor (or angiotensin II subtype 1 receptor antagonist) | thiazide diuretic | calcium channel blocker or beta blocker |
ACE inhibitor (or angiotensin II subtype 1 receptor antagonist) | calcium channel blocker | thiazide diuretic or beta blocker |
beta blocker | thiazide diuretic | ACE inhibitor (or angiotensin II subtype 1 receptor antagonist) or calcium channel blocker |
beta blocker | calcium channel blocker | ACE inhibitor (or angiotensin II subtype 1 receptor antagonist) or thiazide diuretic |